Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Letermovir Prophylaxis for CMV in High-Risk Allo-HSCT Recipients
NCT06812598Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of letermovir in cytomegalovirus infection (CMV) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Incidence of clinically significant CMV infection at 24 weeks. Started Dec 2024; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06812598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812598.